

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8022950

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HERRIOT TABUTEAU	04/28/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ANTECIP BIOVENTURES II LLC
<b>Street Address:</b>	630 FIFTH AVENUE, SUITE 2000
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10111
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	18333944
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(435)252-1361
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	949-202-1903
<b>Email:</b>	Docket@mabr.com
<b>Correspondent Name:</b>	BRENT A. JOHNSON
<b>Address Line 1:</b>	MASCHOFF BRENNAN
<b>Address Line 2:</b>	100 SPECTRUM CENTER DRIVE, SUITE 1200
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92618
<b>ATTORNEY DOCKET NUMBER:</b>	A3226.10063US07
<b>NAME OF SUBMITTER:</b>	MARIA NADAL
<b>SIGNATURE:</b>	/Maria Nadal/
<b>DATE SIGNED:</b>	06/23/2023
<b>Total Attachments: 5</b>	
source=A3226.10063US07 - EXECUTED ASSIGNMENT PARENT#page1.tif	
source=A3226.10063US07 - EXECUTED ASSIGNMENT PARENT#page2.tif	
source=A3226.10063US07 - EXECUTED ASSIGNMENT PARENT#page3.tif	
source=A3226.10063US07 - EXECUTED ASSIGNMENT PARENT#page4.tif	
source=A3226.10063US07 - EXECUTED ASSIGNMENT PARENT#page5.tif	

## ASSIGNMENT

**THIS ASSIGNMENT** is made by **Herriot Tabuteau** (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to **Antecip Bioventures II LLC**, a legal entity having its principal place of business at 630 Fifth Avenue, Suite 2000, New York, New York 10111 (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

**WHEREAS** ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an application(s) for or Letters Patent has been filed as indicated on **Exhibit A** (hereafter "Inventions");

**WHEREAS** ASSIGNOR believes himself to be the original and true inventor of the Inventions;

**WHEREAS** ASSIGNEE desires to acquire the Inventions and improvements thereto;

**AND WHEREAS**, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title, and interest in, to, and under the Inventions and improvements thereto owned by ASSIGNOR;

**NOW THEREFORE**, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

**ASSIGNOR** hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other

legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other administrative or judicial proceeding; and promptly completing any and all actions necessary or desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.

The undersigned hereby grant to the firm of Maschoff Brennan, 100 Spectrum Center Drive, Suite 1200, Irvine CA 92618, the power to insert in this Assignment any further identification which may be necessary or desirable for recordation of this Assignment.

*A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.*

**IN TESTIMONY WHEREOF**, I hereunder set my hand this 10 day of April, 2013

**ASSIGNOR**

**Herriot Tabuteau**

Signature

State of New York           )  
  )     ss.:  
County of                    )

On this \_\_\_\_ day of \_\_\_\_\_, 20\_\_, before me, \_\_\_\_\_, personally appeared **Herriot Tabuteau**, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

\_\_\_\_\_  
Notary Public

*A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached and not the truthfulness accuracy or validity of that document.*

**ACKNOWLEDGED AND CONFIRMED**, I hereunder set my hand this 10 day of April, 2013, as a duly authorized representative of ASSIGNEE.

**ASSIGNEE**

**Antecip Bioventures II LLC**

  
Name: Herriot Tabuteau, MD  
Title: Managing Member

State of New York           )  
  )  
County of                    )           ss.:

On this \_\_\_\_ day of \_\_\_\_\_, 20\_\_, before me, \_\_\_\_\_, personally appeared **Herriot Tabuteau** who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

Witness my hand and official seal.

\_\_\_\_\_  
Notary Public

**EXHIBIT A**

<b><u>Title</u></b>	<b><u>Serial No.</u></b>	<b><u>Filing Date</u></b>
TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN	18/156,825	19 Jan 2023
BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS	18/157,393	20 Jan 2023
BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS	18/157,266	20 Jan 2023
TREATMENT OF DEPRESSION IN CERTAIN PATIENT POPULATIONS	18/158,268	23 Jan 2023
TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN	18/169,571	15 Feb 2023
BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS	18/170,151	16 Feb 2023
TREATMENT OF DEPRESSION IN CERTAIN PATIENT POPULATIONS	18/170,120	16 Feb 2023
TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN	18/172,555	22 Feb 2023
TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN	18/172,617	22 Feb 2023
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS	18/173,291	23 Feb 2023
TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN	18/173,372	23 Feb 2023
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS	18/174,123	24 Feb 2023
METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS	18/174,278	24 Feb 2023
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS	18/175,865	28 Feb 2023

<b>Title</b>	<b>Serial No.</b>	<b>Filing Date</b>
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS	18/175,862	28 Feb 2023
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS	18/177,585	02 Mar 2023
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	18/179,196	06 Mar 2023
METHOD OF REDUCING RISK OF NEUROTOXICITY IN CHILDREN OF LACTATING MOTHERS EXPERIENCING DEPRESSION	18/182,108	10 Mar 2023
COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	18/188,689	23 Mar 2023
COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	18/194,038	31 Mar 2023
COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	18/194,257	31 Mar 2023
COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION\	18/296,851	05 Apr 2023
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	18/298,122	10 Apr 2023
COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	18/303,051	19 Apr 2023
COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION	18/304,246	20 Apr 2023